FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

Telomere Defense Stack

Anti-Aging & Longevityintermediate
33
Share
Pépétides

3

Moyenne journalière en mcg

7,443

Niveau

intermediate

Ajouté

May 16, 2026

Aperçu

The Telomere Defense Stack is an intermediate-level longevity protocol designed to protect and restore chromosomal integrity while optimizing mitochondrial function. This stack addresses two of the most fundamental hallmarks of aging: telomere attrition and mitochondrial dysfunction, making it one of the most scientifically grounded anti-aging peptide combinations available. Epithalon, administered at 5000mcg daily, is the centerpiece of this protocol and the only known peptide demonstrated to activate telomerase in human somatic cells. Developed from decades of research by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Epithalon is a synthetic tetrapeptide that mimics the natural pineal gland peptide Epithalamin. Clinical research has shown it can increase telomere length, normalize circadian rhythm function, and restore melatonin production to youthful levels. By maintaining telomere length, Epithalon helps prevent cells from entering senescence, the state where damaged cells accumulate and drive systemic inflammation and tissue deterioration. MOTS-c, dosed at 5000mcg three times per week, is a mitochondrial-derived peptide that acts as a powerful metabolic regulator. It activates AMPK signaling pathways, improves insulin sensitivity, and enhances cellular energy production. Research has shown MOTS-c can reprogram cellular metabolism to resist age-related decline, improve exercise capacity, and reduce accumulation of metabolic waste products. It works synergistically with Epithalon by ensuring that cells with preserved telomere length also maintain robust energy production capabilities. GHK-Cu at 300mcg daily adds broad-spectrum anti-aging gene modulation to the stack. Studies have identified over 4,000 genes whose expression is positively influenced by GHK-Cu, many of which are involved in DNA repair, antioxidant defense, and stem cell maintenance. This creates a supportive environment for the telomere-protective and mitochondrial effects of the other peptides. This stack is ideal for health-conscious individuals over 35 seeking to address aging at its root causes rather than its symptoms. Run in 20-day cycles with 10-day breaks for Epithalon, while MOTS-c and GHK-Cu can continue uninterrupted. Morning administration is preferred, and periodic telomere length testing can help track progress over multiple cycles.

Protocole de dose

Epithalon

Every day

Lire plus sur Epithalon →

5,000 mcg

par dose

MOTS-c

3 times per week

Lire plus sur MOTS-c →

5,000 mcg

par dose

300 mcg

par dose

Objectifs & Preuves

Niveau d'évidence :community

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.